This morning, the Federal Circuit released one precedential opinion, one nonprecedential opinion, and one nonprecedential order. The precedential opinion comes in a patent case appealed from the Southern District of Texas. The nonprecedential opinion comes in another patent case appealed from the Patent Trial and Appeal Board. The nonprecedential order dismisses an appeal. Here are the introductions to the opinions as well as a link to the dismissal.
VDPP, LLC v. Volkswagen Group Group of America, Inc. (Precedential)
VDPP, LLC (VDPP) appeals orders of the United States District Court for the Southern District of Texas (1) dismissing VDPP’s complaint without granting leave to amend, (2) awarding attorney fees to Volkswagen under 35 U.S.C. § 285, and (3) sanctioning VDPP’s counsel, William Peterson Ramey, III. For the following reasons, we affirm-in-part and dismiss-in-part.
10X Genomics, Inc. v. Parse Biosciences, Inc. (Nonprecedential)
10x Genomics (“10x”) appeals final written decisions by the Patent Trial and Appeal Board in inter partes reviews (“IPRs”) brought by Parse Biosciences, Inc. (“Parse”). The Board determined that all claims of U.S. Patent No. 10,155,981 (“the ’981 patent”), U.S. Patent No. 10,240,197 (“the ’197 patent”), and U.S. Patent No. 10,697,013 (“the ’013 patent”), are unpatentable as obvious. Parse Biosciences, Inc. v. 10x Genomics, Inc., No. IPR2023-00876, 2024 WL 4218540, at *1 (P.T.A.B. Sep. 17, 2024) (“’981 Decision”); Parse Biosciences, Inc. v. 10x Genomics, Inc., No. IPR2023-00955, 2025 WL 355170, at *1 (P.T.A.B. Jan. 31, 2025) (“’197 Decision”); Parse Biosciences, Inc. v. 10x Genomics, Inc., No. IPR2023- 00958, 2025 WL 383299, at *1 (P.T.A.B. Feb. 3, 2025) (“’013 Decision”). For the reasons below, we affirm.